WO2024258870A8 - Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine - Google Patents

Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine

Info

Publication number
WO2024258870A8
WO2024258870A8 PCT/US2024/033443 US2024033443W WO2024258870A8 WO 2024258870 A8 WO2024258870 A8 WO 2024258870A8 US 2024033443 W US2024033443 W US 2024033443W WO 2024258870 A8 WO2024258870 A8 WO 2024258870A8
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
receptor agonist
beta receptor
agonist binding
lymphotoxin beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033443
Other languages
English (en)
Other versions
WO2024258870A2 (fr
Inventor
Rajkumar NOUBADE
Ian Nevin FOLTZ
Hong Yu Wang
Danyang GONG
Ryan Benjamin CASE
Jun Zhang
Chin-Wen Lai
Fernando Garces
Christine Elaine Tinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202480038870.XA priority Critical patent/CN121399157A/zh
Priority to AU2024305352A priority patent/AU2024305352A1/en
Priority to KR1020267000619A priority patent/KR20260025131A/ko
Priority to EP24741027.7A priority patent/EP4724490A2/fr
Priority to PE2025003091A priority patent/PE20260306A1/es
Priority to IL325097A priority patent/IL325097A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of WO2024258870A2 publication Critical patent/WO2024258870A2/fr
Publication of WO2024258870A8 publication Critical patent/WO2024258870A8/fr
Priority to JOJO/P/2025/0305A priority patent/JOP20250305A1/ar
Anticipated expiration legal-status Critical
Priority to MX2025015224A priority patent/MX2025015224A/es
Priority to CONC2025/0018800A priority patent/CO2025018800A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2024/033443 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine Ceased WO2024258870A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2024305352A AU2024305352A1 (en) 2023-06-12 2024-06-11 Lymphotoxin beta receptor agonist binding proteins
KR1020267000619A KR20260025131A (ko) 2023-06-12 2024-06-11 림포톡신 베타 수용체 작용제 결합 단백질
EP24741027.7A EP4724490A2 (fr) 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
PE2025003091A PE20260306A1 (es) 2023-06-12 2024-06-11 Proteinas de union a receptor de linfotoxina beta agonistas
IL325097A IL325097A (en) 2023-06-12 2024-06-11 Lymphotoxin receptor agonist binding proteins
CN202480038870.XA CN121399157A (zh) 2023-06-12 2024-06-11 淋巴毒素β受体激动剂结合蛋白
JOJO/P/2025/0305A JOP20250305A1 (ar) 2023-06-12 2025-12-11 البروتينات الرابطة المنشطة لمستقبل الليمفوتوكسين بيتا
MX2025015224A MX2025015224A (es) 2023-06-12 2025-12-15 Proteinas de union a receptor de linfotoxina beta agonistas
CONC2025/0018800A CO2025018800A2 (es) 2023-06-12 2025-12-24 Proteínas de union a agonistas del receptor de linfoxina beta

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12
US63/472,565 2023-06-12

Publications (2)

Publication Number Publication Date
WO2024258870A2 WO2024258870A2 (fr) 2024-12-19
WO2024258870A8 true WO2024258870A8 (fr) 2025-12-11

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033443 Ceased WO2024258870A2 (fr) 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine

Country Status (14)

Country Link
EP (1) EP4724490A2 (fr)
KR (1) KR20260025131A (fr)
CN (1) CN121399157A (fr)
AR (1) AR132931A1 (fr)
AU (1) AU2024305352A1 (fr)
CL (1) CL2025003919A1 (fr)
CO (1) CO2025018800A2 (fr)
IL (1) IL325097A (fr)
JO (1) JOP20250305A1 (fr)
MX (1) MX2025015224A (fr)
PE (1) PE20260306A1 (fr)
TW (1) TW202506733A (fr)
UY (1) UY40783A (fr)
WO (1) WO2024258870A2 (fr)

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP5138867B2 (ja) 2002-08-01 2013-02-06 イミューノメディクス、インコーポレイテッド α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AU2006265936A1 (en) 2005-07-01 2007-01-11 Medimmune, Llc An integrated approach for generating multidomain protein therapeutics
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
CA2682390A1 (fr) 2007-04-17 2008-10-30 Imclone Llc Inhibiteurs specifiques de pdgfr.beta.
ME02345B (fr) 2007-07-17 2016-08-31 Squibb & Sons Llc Anticorps monoclonaux contre le glypicane-3
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
AU2008337517B2 (en) 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EP2236517A1 (fr) 2009-03-31 2010-10-06 Takara Bio, Inc. Anticorps monoclonal à fragment anti-fibronectine
AU2010249531A1 (en) 2009-05-21 2011-12-15 Tamarisk Technologies, L.L.C. Alginate-based building materials
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
KR101528013B1 (ko) 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
WO2011130580A1 (fr) 2010-04-15 2011-10-20 Alper Biotech, Llc Anticorps monoclonaux contre antigènes her2 et leurs utilisations
EP2563816B1 (fr) 2010-04-27 2014-11-12 National Research Council of Canada Anticorps à domaine unique anti-icam-1 et leurs utilisations
WO2011139375A1 (fr) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
CA2800488A1 (fr) 2010-05-26 2011-12-01 Regents Of The University Of Minnesota Anticorps anti-cd133 a fragment variable a chaine simple et ses utilisations
EP2576621B1 (fr) 2010-05-27 2019-04-10 Genmab A/S Anticorps monoclonaux contre her2
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
EP2595657A4 (fr) 2010-07-22 2015-09-23 Univ California Anticorps-antigènes antitumoraux et méthodes d'utilisation correspondantes
JP5883443B2 (ja) 2010-07-22 2016-03-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規の抗原結合タンパク質
WO2012163771A1 (fr) 2011-06-03 2012-12-06 Ct Atlantic Ltd. Anticorps se liant à mage a3
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
EP2548891A1 (fr) 2011-07-18 2013-01-23 Universiteit Maastricht Anticorps monoclonal humain contre la subunité gamma du récepteur de l'acétylcholine pour une utilisation dans le traitement du rhabdomyosarcome
CA2890483A1 (fr) 2012-11-09 2014-05-15 Robert ARCH Anticorps specifiques du facteur de croissance b derive des plaquettes, leurs compositions et leurs utilisations
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
CN117843785A (zh) 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
LT3030581T (lt) 2013-08-07 2021-05-25 Affimed Gmbh Antikūno surišimo vietos specifiškos egfrviii
JP6632984B2 (ja) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
KR20160145119A (ko) 2014-05-14 2016-12-19 에프. 호프만-라 로슈 아게 Her1의 베타-헤어핀에 결합하는 her1 항원 결합 단백질
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
EP4245376A3 (fr) 2014-10-14 2023-12-13 Novartis AG Molécules d'anticorps de pd-l1 et leurs utilisations
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
WO2016154623A2 (fr) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps monoclonaux anti-cd133 et compositions et méthodes associées
EP4019552A1 (fr) 2015-06-10 2022-06-29 National Research Council of Canada Anticorps spécifiques de l'anhydrase carbonique ix et leurs utilisations
HK1248255A1 (zh) 2015-06-24 2018-10-12 优瑞科生物技术公司 靶向ny-eso-1肽/mhc复合物的构建体及其用途
MA46046A (fr) 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
EP3684818A2 (fr) 2017-09-21 2020-07-29 UMC Utrecht Holding B.V. Anticorps anti-gd2 pour le traitement du neuroblastome
CA3080120C (fr) 2017-10-27 2023-11-21 New York University Anticorps anti-galectine-9 et leurs utilisations
MX2020006119A (es) 2017-12-21 2020-08-24 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1.
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
WO2020003210A1 (fr) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anticorps anti-l1cam et leurs utilisations
WO2020025792A1 (fr) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Constructions d'anticorps pour cldn18.2 et cd3
CA3116314A1 (fr) 2018-10-15 2020-04-23 Board Of Regents, The University Of Texas System Anticorps monoclonaux diriges contre la dickkopf3 humaine et leurs utilisations
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations

Also Published As

Publication number Publication date
CN121399157A (zh) 2026-01-23
AR132931A1 (es) 2025-08-13
CL2025003919A1 (es) 2026-01-23
IL325097A (en) 2026-02-01
JOP20250305A1 (ar) 2025-12-11
AU2024305352A1 (en) 2025-12-04
WO2024258870A2 (fr) 2024-12-19
EP4724490A2 (fr) 2026-04-15
PE20260306A1 (es) 2026-02-11
MX2025015224A (es) 2026-02-03
KR20260025131A (ko) 2026-02-23
CO2025018800A2 (es) 2026-03-26
UY40783A (es) 2024-12-31
TW202506733A (zh) 2025-02-16

Similar Documents

Publication Publication Date Title
PL4069686T3 (pl) Agonista receptora glp-1
EP4095149A4 (fr) Triple agoniste pour récepteur du peptide-1 type glucagon, récepteur du glucagon, et récepteur du polypeptide inhibiteur gastrique
MA55529A (fr) Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
EP4019524A4 (fr) Composé agoniste du récepteur thr-bêta hétérocyclique, son procédé de préparation et son utilisation
CA3265218A1 (fr) Protéines de fusion de récepteurs de lymphocytes t spécifiques de mage a4
EP4159722A4 (fr) Procédé de préparation d'agoniste du récepteur glp-1
AU2024305352A1 (en) Lymphotoxin beta receptor agonist binding proteins
CA3295009A1 (fr) Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
HK40106103A (en) Thyroid hormone receptor beta agonist compounds
CA3275875A1 (fr) Protéines de liaison au récepteur de la transferrine
HK40074189A (en) Thyroid hormone receptor beta agonist compounds
CA3296481A1 (fr) Polythérapie avec des agonistes du récepteur bêta de la lymphotoxine ciblant fap
CA3276371A1 (fr) Agonistes du récepteur de la galanine-2
CA3275190A1 (fr) Formulations d'agoniste de récepteur d'hormone inhalable
HK40108078A (en) Fusion protein containing improved glp-1 receptor agonist and uses
HK40108106A (en) Polymorph as thyroid hormone receptor agonists and use thereof
HK40122612A (en) Glucocorticoid receptor agonists
HK40120463A (en) T cell receptor fusion proteins specific for mage a4
HK40055638A (en) Thyroid hormone receptor beta agonist compounds
AU2023900379A0 (en) Antibodies for binding CCR6
AU2022900319A0 (en) Antibodies for binding CCR6
HK40102463A (en) Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists
CA3283074A1 (fr) Agoniste du récepteur beta de l'hormone thyroidienne polycyclique et son utilisation
HK40068712A (en) Anti-alpha beta tcr binding polypeptides with reduced fragmentation
HK40124254A (en) Glucagon-like peptide 1 receptor agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24741027

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: AU2024305352

Country of ref document: AU

Ref document number: 827438

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 827438

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 325097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2024305352

Country of ref document: AU

Date of ref document: 20240611

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CN202480038870X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: P2025-04030

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 2501008501

Country of ref document: TH

Ref document number: 202517125869

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/015224

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025027542

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: DZP2025001884

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 202593502

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 202517125869

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 325097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 1020267000619

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000619

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 2024741027

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 11202508343V

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508343V

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: MX/A/2025/015224

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: 1020267000619

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2024741027

Country of ref document: EP